Abstract: This disclosure provides methods of manufacturing large-scale blended preparations comprising one or more amino acids wherein the preparations have certain properties.

Abstract: Provided in accordance with the present disclosure are methods for preventing or reducing cognitive dysfunction or decline associated with an acquired brain injury, for treating cognitive dysfunction or decline associated with an acquired brain injury, and for inducing or increasing neuroplasticity, the methods comprising administering to a subject in need thereof a therapeutically effective amount of trehalose.

Abstract: The present invention relates to a physicochemically stable pharmaceutical composition, in a unit dose characterized in that it comprises effective amounts of 5 the active ingredients thiamine (Vitamin B1), pyridoxine (Vitamin B6), a flavonoid such as quercetin and a polyphenol such as curcumin, or their pharmaceutically acceptable salts in combination with pharmaceutically acceptable excipients, for the prevention of the formation and/or trapping of advanced glycation end products (glyoxal, methylglyoxal, Ni-carboxymethyl-iysine, N-carboxyethyl-lysine, pyrraline, pentosidine, lysine dimer, etc.), which can be used in the treatment and/or prevention of complications of diabetes mellitus (diabetic neuropathy, nephropathy and retinopathy). The pharmaceutical composition of the invention is presented orally, preferably in capsule, pill or sachet for oral administration.

Abstract: The present invention provides a suspension comprising aluminum hydroxide and magnesium hydroxide and a method of preparing the same. The aqueous suspension composition according to the present invention ensures an excellent sedimentation rate by using a mixed suspending agent with a specific composition, so that insoluble aluminum hydroxide and magnesium hydroxide do not easily settle, do not form a cake, and are easily redispersed. Since the aqueous suspension composition having an excellent sedimentation rate has not only physical stability, but also forms a homogeneous dispersion system, the reproducibility or effectiveness of bioavailability may be ensured. In addition, the aqueous suspension composition according to the present invention provides an excellent texture, and thus patient compliance increases.

Abstract: The present disclosure relates to a pharmaceutical solution having a toxicity-reducing effect for anti-tumor drugs, and a pharmaceutical composition comprising the solution as well as a method for using them. The pharmaceutical solution uses deuterium oxide as a solvent.

Abstract: The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.

Abstract: The invention provides pharmaceutical compositions having improved effects and synergistic efficacy against pain, and provides methods for their use to treat pain, wherein the composition comprises: a sulfur-containing amino acid; a carnitine compound; and at least one compound that is a L-citrulline compound or a beta-alanine compound.

Abstract: The present invention relates to a composition of pH in the range 2.0 to 4.5 comprising at least one fluoride source and at least one other agent for use in prevention and/or treatment of dental erosion.

Abstract: The present disclosure provides methods of generating germ layers from stem cells comprising culturing the stem cells in a culture medium having an osmolality less than 340 mOsm/kg. The present disclosure also includes a method to generate different cell lineages from the germ layers as well as to detect them by immunological methods. The present disclosure further provides methods for the generation, isolation, cultivation and propagation of committed progenitor cells and for the production of differentiated cells from the three germ layers. The present disclosure also provides culture media for use in inducing the three germ layers.

Abstract: Liquid dietary supplement formulation compositions that provide dietary minerals and additional optional ingredients beneficial for health; methods for manufacturing such compositions; and methods for enabling convenient oral ingestion of the formulation ingredients, by adding the same to drinking water, beverages, foods, or meals. The inventive formulation compositions generally include water, water-soluble calcium compound(s), water-soluble magnesium compound(s), and additional optional ingredients, wherein the sum of the concentrations of the calcium and magnesium compounds is most preferably 2 molar or more, up to the point of saturation. The inventive formulation compositions possess inherent resistance to microbial growth.

Abstract: Provided is a fibrous product that has excellent anti-allergen and antiviral properties, is capable of maintaining excellent outer appearance, and is less likely to cause color migration. Also provided is a processing agent for producing the fibrous product. The fibrous product of the present invention is characterized in having attached to the surface thereof (a) 1.0 to 3.0 g/m2 of zirconium phosphate, (b) 0.12 to 0.4 g/m2 of a homopolymer formed of an aromatic sulfonic acid monomer, and (c) 0.2 to 0.8 g/m2 of a copolymer including a styrene sulfonate salt. In addition, the processing agent of the present invention is characterized in being an aqueous dispersion that contains the components (a), (b), and (c) in a weight ratio of 1.0 to 3.0:0.12 to 0.4:0.2 to 0.8.

Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

Abstract: Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.

Abstract: Methods and compositions of reducing or eliminating the symptoms of withdrawal from drug or alcohol in drug or alcohol-dependent persons, while restoring the patient to nutritional health. The methods including parenteral administration of solutions containing high doses of ascorbic acid, including the serial administration of doses of ascorbic acid that differ in concentration by at least 10 fold (by weight). Compositions of the invention comprise at least about 20% (w),or at least about 25% (w), or at least about 30% (w), or at least about 35% (w), or at least about 38% (w) of ascorbic acid and a local anesthetic.

Abstract: This invention relates to liquid dietary supplement formulation compositions that provide dietary minerals and additional optional ingredients beneficial for health; methods of design and manufacture of such compositions; and methods to enable convenient oral ingestion of the formulation ingredients, by adding the formulations to drinking water, beverages, foods, or meals. The formulation compositions of this invention generally include water, water-soluble calcium compound(s), water-soluble magnesium compound(s), and additional optional ingredients, wherein the sum of the concentrations of the calcium and magnesium compounds is most preferably 2 molar or more, up to the point of saturation. The formulations of this invention possess inherent resistance to microbial growth.

Abstract: The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin.

Abstract: Liquid metabolic formulas for dietary management of tyrosinemia, including nutritional formulas and hydration beverages (sport drinks).

Abstract: A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 ?M, and rubidium in a concentration of 1.4-4.2 ?M. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper.

Abstract: A therapeutic rinse for treating a sore throat. The therapeutic rinse may be stored in a self-heating container that is capable of reaching a temperature of at least 130 degrees Fahrenheit when activated. The therapeutic rinse includes a liquid composition having sodium chloride, water, and a variety of vitamins, minerals and herbs stored in the reservoir of the self-heating container. An antibiotic may also be included in the therapeutic rinse. Before use, the therapeutic rinse may be heated.

Abstract: The present invention provides a composition for improving mind-concentration, characterized in that the composition comprises theanine; and a method of improving mind-concentration comprising administering theanine to an individual.

Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

Abstract: Disclosed are methods for improving nitrogenous acid (e.g., creatine) solubility, and products made by the method.

Abstract: This is a process to make a shelf-stable, liquid, ready-to-drink, aseptic nutritional formula for the treatment of PKU, tyrosinemia or other errors of metabolism. The liquid nutritional formula has caseino-glyco-macropeptide as the primary protein source and complementary essential amino acids to complete the requirement profile. The beverage also includes vitamins and minerals sufficient to meet daily requirements. When used as a complete diet, the nutritional formula includes a carbohydrate source and a fat source. The nutritional formula has a pleasant taste.

Abstract: The invention provides an easy-to-drink beverage that contains citrulline, wherein the generation of bad odors due to storage or heating is suppressed. In particular, the invention provides a beverage that contains citrulline, citric acid, sodium citrate, water, and one or more supplements that are saccharides, souring agents, preservatives, colorants, flavoring agents, functional ingredients, or carbon dioxide.

Abstract: Pigs infected with PEDv often die due to dehydration caused by diarrhea. Those that survive do not reach market weight as scheduled resulting in costs to the producer. The invention includes providing electrolyzed water either as treatment for infected animals or as a prophylactic against symptom severity in uninfected animals. The electrolyzed water is used as a substitute for or as a solution with regular drinking water. Duration of symptoms for infected pigs is markedly lessened; severity of symptoms is also reduced providing a much higher survival rate. Time to market is less negatively affected for surviving pigs than those untreated, and weight at scheduled time for sale is also less effected translating into positive financial results over those expected for untreated herds.

Abstract: A method of treating a plant against a fungal and/or bacterial plant pathogen includes applying to a plant infected with a fungal and/or bacterial plant pathogen an effective amount of composition comprising a salicylate, potassium polyphosphite, and potassium phosphite. A method of fertilizing a plant and treating the plant against a bacterial and/or fungal plant pathogen includes applying to a plant an effective amount of composition comprising a salicylate, potassium polyphosphite, potassium phosphite, and potassium phosphate.

Abstract: A method for controlling microbial or biofilm growth in a medium includes mixing ammonium carbamate or ammonium sulfamate with an aqueous solution of a hypochlorite oxidant to form a biocide having a pH between 9.0 and 11.5, the molar ratio of the ammonium carbamate or ammonium sulfamate to the hypochlorite being at least 1:1; and then applying the biocide to the medium.

Abstract: The present invention relates to a medical solution, a method for producing said medical solution, a multi-compartment bag containing the medical solution as well as use of said medical solution. According to the invention the medical solution comprises a first single solution comprising bicarbonate and carbonate in such proportions that the partial pressure of carbon dioxide, CO2, in the first single solution is of the same order of magnitude as the partial pressure of carbon dioxide, CO2, of the atmosphere. The medical solution further comprises a second single solution comprising an acid. Said first and second single solutions are, after terminal sterilization and up on use, to be mixed to form a final solution. Said second single solution has a pH of 1.0-1.5, and said final solution has a pH of 7.0-7.6.

Abstract: Oral compositions containing a polyorganosilsesquioxane particle, preferably polymethylsilsesquioxane particles, an oxidizing agent and an orally-acceptable carrier. Method of using such compositions for the cleaning and polishing of dental enamel, such methods including the step of applying such oral care compositions to the teeth of a user.

Abstract: An alkaline sports drink that utilizes phosphate buffer to achieve a pH of 7.4(+/?0.3) for the purpose of preventing dental caries, improving physical performance, and benefiting overall health, is disclosed. This beverage product is stable at an alkaline pH, which is beneficial for oral health and the use of phosphate buffer increases physical performance by increasing muscle oxygen availability. The product is beneficial to overall health by buffering harmful acidic metabolites and aiding in their excretion from the body.

Abstract: The present invention provides methods for inhibiting complement activation and uses thereof. More specifically, the present invention provides methods for inhibiting complement activation using polyphosphates.

Abstract: Methods of using a polymeric composition are described for preventing or reducing the signs of aging. The polymeric composition can include a polymer matrix and one or a plurality of mineral filler(s), uniformly dispersed in the polymer matrix, having properties of absorption and/or emission in the far infrared region ranging from 2 ?m to 20 ?m.

Abstract: A method of use of silicon substituted phosphates that improves bone and soft tissue growth resulting in better adhesion and fixation of implanted prosthetics, which may be used as part of a tissue engineering scaffold for ligament replacement and results in improved healing of healing of damaged bone and soft tissue ulcers. The silicon substituted phosphates of various chemical composition and granular sizes may be used in direct application or in combination with other materials, not previously claimed in prior art used to treat the various medical conditions described.

Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

Abstract: Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling.

Abstract: Disclosed are systems, methods, compositions and kits for mineralizing tissue, particularly dental tissue. The methods, compositions and kits may be used to strengthen and prevent weakening of the tissue. For example, the methods, compositions and kits may be used for treating and filling cavities in teeth caused by tooth decay.

Abstract: The present disclosure is directed toward a composition and method of treating and preventing infection of pathogenic microorganisms and endopyhtic microorganisms in a plant through the use of phosphite compositions.

Abstract: The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

Abstract: A method is provided for promoting blood clotting. The area which is bleeding is contacted with an aluminophosphate molecular sieve. The molecular sieve preferably contains a substance which assists the clotting of blood. This substance is preferably Ca2+ ions, which are readily introduced into aluminophosphate molecular sieves. Preferred aluminophosphate molecular sieves include AlPO4-5 and VPI-5.

Abstract: The invention relates to a material that can be used as a bone substitute and to a method for the preparation thereof. The material comprises an organic phase (I) comprising striated collagen fibrils constituted of collagen I triple helices, said fibrils being organized over a large distance according to a 3D geometry associating aligned domains and cholesteric domains, and also isotropic domains where they are not organized; and a mineral phase (II) comprising apatite crystals having a hexagonal crystalline structure, space group 6/m, comprising at least calcium ions and phosphate ions; the axis c of said apatite crystals of the mineral phase is coaligned with the longitudinal axis of the striated collagen fibrils of the organic phase and the collagen content in the material is at least 75 mg/cm3.

Abstract: There is disclosed a composition for converting electromagnetic energy to ultraviolet C (UVC) radiation or radiation of a shorter wavelength, the composition comprising at least one phosphor capable of converting an initial electromagnetic energy (A) to an electromagnetic energy (B) comprising UVC radiation or radiation of a shorter wavelength, and an organic or inorganic media containing said phosphor. There is also a method of sterilizing an article by exposing it to UVC radiation or radiation of a shorter wavelength for a time sufficient to deactivate or kill at least one microorganism and/or for a time sufficient to inhibit abnormal cell growth within the body, when said composition is in an implantable medical device. A method of coating an article with such compositions is also disclosed.

Abstract: There is disclosed various devices and articles comprising phosphors for converting electromagnetic energy to radiation having a shorter wavelength, the composition comprising at least one phosphor capable of converting an initial electromagnetic radiation having a wavelength (A) to an electromagnetic radiation having a shorter wavelength (B) comprising UV radiation or radiation of a shorter wavelength. There is also a method of sterilizing such devices and articles by exposing it to UV radiation or radiation of a shorter wavelength for a time sufficient to deactivate or kill at least one microorganism and/or for a time sufficient to inhibit abnormal cell growth within the body, when the composition is in an implantable medical device.

Abstract: Beta glucan and fulvic acid can be combined in a dietary supplement as a partial substitute or complete replacement for blue green algae and/or brown seaweed and its derivatives. Beta glucans are widely available as derivatives of Brewer's yeast and fulvic acid is widely available as well. These supplements are not subject to the vagaries of weather-influence growing seasons as is the case with blue green algae and brown seaweed. When combined, beta glucan and fulvic acid can provide a less costly dietary supplement than blue green algae and brown seaweed and its derivatives such as fucoidan.

Abstract: This invention is a pharmaceutical composition comprising of lithium as an active ingredient, to decrease intracellular calcium ion concentrations, and a beta-secretase inhibitor as an active ingredient, to reduce beta-secretase activity; for the treatment and prevention of disease, including disease characterized by the abnormal cleavage of amyloid precursor protein.

Abstract: A bone graft substitute in the form of an implantable three-dimensional scaffold that includes calcium phosphate and has pores. The scaffold is impregnated with a calcium and/or phosphate containing substance, and the dissolution rate DRS of the scaffold is slower than the dissolution rate DRD of the calcium and/or phosphate containing substance.

Abstract: Compositions and formulations comprising a non-neutralised tocol phosphate and a vitamin A compound, which are suitable for the treatment of inflammation and/or infection in breast or udder tissue, more particularly in a mammary gland, reducing the somatic cell count in a lactating subject and supplementing vitamin E levels in a subject.

Abstract: The invention relates to hardenabie ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenabie bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

Abstract: A system and process for generating and packaging phosphine gas, in which the process includes: reacting water and aluminum phosphide to generate phosphine, and providing the phosphine in a gas mixture at a phosphine concentration below a lower explosive limit; adsorptively removing phosphine from the gas mixture; and packaging the removed phosphine in a fluid storage and dispensing vessel.

Abstract: The described pKa process creates a unique combination of active ingredients. The calcium carbonate carrier is impregnated with various proportions of active ingredients and the compounds are made more effective by the sheer and absorption action as they are combined in the described process. The calcium carrier is adjusted to incorporate small amounts of highly efficient/effective pH adjusters. No natural solution exists in Nature with a pH of 10.6 that is optimal for adjusting the pKa naturally in foods. The present invention effects a change in the pKa of most acids and therefore impacts pH which can positively affect flavor, color and taste. The reduced moisture process in combination with the invention solution applied as a treatment results in fruits and vegetables that exhibit cleaner flavors, better texture, enhanced color and lower microbial counts than is found in standard IQF vegetables currently available.

Abstract: The present disclosure is directed toward a composition and method of treating and preventing infection of pathogenic microorganisms and endopyhtic microorganisms in a plant through the use of phosphite compositions.